Skip to content

A prospective multicenter clinical trial of effect of different stent removal strategies on post-ERCP pancreatitis

A prospective multicenter clinical trial of effect of different stent removal strategies on post-ERCP pancreatitis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047373
Enrollment
Unknown
Registered
2021-06-13
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-ERCP pancreatitis

Interventions

Group A:Removal of biliary calculi is prior to removal of pancreatic duct stent
Group B:Removal of pancreatic duct stent is prior to removal of biliary calculi

Sponsors

Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. MRCP found common bile duct stones, and ERCP stone removal is feasible (the number of stones should be marked with >5 or < 5); 3. During the ERCP operation, the surgeon judges that the stones can be removed by a single ERCP; 4. It can also be included after cholecystectomy or liver lobectomy after previous gallbladder surgery or planned short-term cholecystectomy; 5. Subjects voluntarily participate in this trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with coagulation dysfunction (INR>1.3) and peripheral platelet counts are significantly reduced < 50x10^9/L; 2. Acute pancreatitis before surgery; 3. Combined with biliary hemorrhage before operation; 4. Combined with severe liver disease, primary sclerosing cholangitis; 5. Combined with Mirizzi syndrome, intrahepatic bile duct stones; 6. Combined with malignant tumors of the hepatobiliary and pancreatic system; 7. With obvious stenosis of the lower part of the bile duct; 8. Bile duct duodenal fistula was found during the operation; 9. A history of gastrointestinal reconstruction surgery; 10. Other ERCP contraindications.

Design outcomes

Primary

MeasureTime frame
Abdominal pain;Blood biochemical indexes;Morphology of pancreas;

Countries

China

Contacts

Public ContactWu Wen'guang

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

wuwenguang08@126.com+86 13681991611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026